OBJECTIVE: To characterize the diversity and taxonomic relative abundance of the gut microbiota in patients with never-treated, recent-onset psoriatic arthritis (PsA). METHODS: High-throughput 16S ribosomal RNA pyrosequencing was utilized to compare the community composition of gut microbiota in patients with PsA (n = 16), patients with psoriasis of the skin (n = 15), and healthy, matched control subjects (n = 17). Samples were further assessed for the presence and levels of fecal and serum secretory IgA (sIgA), proinflammatory proteins, and fatty acids. RESULTS: The gut microbiota observed in patients with PsA and patients with skin psoriasis was less diverse when compared to that in healthy controls. This could be attributed to the reduced presence of several taxa. Samples from both patient groups showed a relative decrease in abundance of Coprococcus species, while samples from PsA patients were also characterized by a significant reduction in Akkermansia, Ruminococcus, and Pseudobutyrivibrio. Supernatants of fecal samples from PsA patients revealed an increase in sIgA levels and decrease in RANKL levels. Analysis of fatty acids revealed low fecal quantities of hexanoate and heptanoate in both patients with PsA and patients with psoriasis. CONCLUSION: Patients with PsA and patients with skin psoriasis had a lower relative abundance of multiple intestinal bacteria. Although some genera were concomitantly decreased in both conditions, PsA samples had a lower abundance of reportedly beneficial taxa. This gut microbiota profile in PsA was similar to that previously described in patients with inflammatory bowel disease and was associated with changes in specific inflammatory proteins unique to this group, and distinct from that in patients with skin psoriasis and healthy controls. Thus, the role of the gut microbiome in the continuum of psoriasis-PsA pathogenesis and the associated immune response merits further study.
OBJECTIVE: To characterize the diversity and taxonomic relative abundance of the gut microbiota in patients with never-treated, recent-onset psoriatic arthritis (PsA). METHODS: High-throughput 16S ribosomal RNA pyrosequencing was utilized to compare the community composition of gut microbiota in patients with PsA (n = 16), patients with psoriasis of the skin (n = 15), and healthy, matched control subjects (n = 17). Samples were further assessed for the presence and levels of fecal and serum secretory IgA (sIgA), proinflammatory proteins, and fatty acids. RESULTS: The gut microbiota observed in patients with PsA and patients with skin psoriasis was less diverse when compared to that in healthy controls. This could be attributed to the reduced presence of several taxa. Samples from both patient groups showed a relative decrease in abundance of Coprococcus species, while samples from PsA patients were also characterized by a significant reduction in Akkermansia, Ruminococcus, and Pseudobutyrivibrio. Supernatants of fecal samples from PsA patients revealed an increase in sIgA levels and decrease in RANKL levels. Analysis of fatty acids revealed low fecal quantities of hexanoate and heptanoate in both patients with PsA and patients with psoriasis. CONCLUSION:Patients with PsA and patients with skin psoriasis had a lower relative abundance of multiple intestinal bacteria. Although some genera were concomitantly decreased in both conditions, PsA samples had a lower abundance of reportedly beneficial taxa. This gut microbiota profile in PsA was similar to that previously described in patients with inflammatory bowel disease and was associated with changes in specific inflammatory proteins unique to this group, and distinct from that in patients with skin psoriasis and healthy controls. Thus, the role of the gut microbiome in the continuum of psoriasis-PsA pathogenesis and the associated immune response merits further study.
Authors: Robert Winchester; Gregory Minevich; Valeria Steshenko; Brian Kirby; David Kane; David A Greenberg; Oliver FitzGerald Journal: Arthritis Rheum Date: 2011-10-17
Authors: Marie Joossens; Geert Huys; Margo Cnockaert; Vicky De Preter; Kristin Verbeke; Paul Rutgeerts; Peter Vandamme; Severine Vermeire Journal: Gut Date: 2011-01-05 Impact factor: 23.059
Authors: Merja Ruutu; Gethin Thomas; Roland Steck; Mariapia A Degli-Esposti; Martin S Zinkernagel; Kylie Alexander; Jared Velasco; Geoffrey Strutton; Ai Tran; Helen Benham; Linda Rehaume; Robert J Wilson; Kristine Kikly; Julian Davies; Allison R Pettit; Matthew A Brown; Michael A McGuckin; Ranjeny Thomas Journal: Arthritis Rheum Date: 2012-07
Authors: Marcelo Vizoná Liberato; Alessandro S Nascimento; Steven D Ayers; Jean Z Lin; Aleksandra Cvoro; Rodrigo L Silveira; Leandro Martínez; Paulo C T Souza; Daniel Saidemberg; Tuo Deng; Angela Angelica Amato; Marie Togashi; Willa A Hsueh; Kevin Phillips; Mário Sérgio Palma; Francisco A R Neves; Munir S Skaf; Paul Webb; Igor Polikarpov Journal: PLoS One Date: 2012-05-23 Impact factor: 3.240
Authors: Josep Bassaganya-Riera; Monica Viladomiu; Mireia Pedragosa; Claudio De Simone; Adria Carbo; Rustem Shaykhutdinov; Christian Jobin; Janelle C Arthur; Benjamin A Corl; Hans Vogel; Martin Storr; Raquel Hontecillas Journal: PLoS One Date: 2012-02-21 Impact factor: 3.752
Authors: Jennifer D Kinslow; Lisa K Blum; Kevin D Deane; M Kristen Demoruelle; Yuko Okamoto; Mark C Parish; Sarah Kongpachith; Lauren J Lahey; Jill M Norris; William H Robinson; V Michael Holers Journal: Arthritis Rheumatol Date: 2016-10 Impact factor: 10.995